Related Experiment Video

Updated: Jun 1, 2025

The Intra-Aortic Balloon Pump
06:13

The Intra-Aortic Balloon Pump

Published on: February 5, 2021

20.9K

Treatment of Cardiogenic Shock: Inotropes, Vasopressors and Machines

Eunice Yun Kwan Choi1, Hoong Sern Lim2,3

  • 1Royal Stoke University Hospital, University Hospitals of North Midlands NHS Foundation Trust, Stoke-On-Trent, UK.

British Journal of Hospital Medicine (London, England : 2005)
|January 20, 2025
PubMed

Insights

Cardiogenic shock (CS) management has improved with new drugs and devices. The DanGer shock trial demonstrated reduced mortality in acute myocardial infarction CS patients, suggesting a future phenotype-guided approach.

Area of Science:

  • Cardiology
  • Critical Care Medicine

Background:

  • Cardiogenic shock (CS) presents a high mortality risk.
  • Pharmacological therapies and mechanical circulatory support (MCS) have advanced CS treatment.
  • Variability exists in the efficacy and safety of current CS interventions.

Purpose of the Study:

  • To summarize current pharmacological and mechanical circulatory support (MCS) treatments for cardiogenic shock (CS).
  • To highlight the implications of recent clinical trials, such as the DanGer shock trial, on CS management strategies.

Main Methods:

  • Review of contemporary pharmacological agents used in CS management.
  • Overview of available mechanical circulatory support (MCS) devices for CS.
  • Analysis of findings from key clinical trials, including the DanGer shock trial.

Main Results:

  • The DanGer shock trial significantly reduced 6-month mortality in CS patients with acute myocardial infarction.
  • Current treatments involve a range of pharmacotherapies and MCS options.
  • Treatment efficacy and safety profiles differ across available interventions.

Conclusions:

  • A phenotype-guided pharmaco-MCS approach is recommended for future randomized trials in CS management.
  • Continued research is essential to optimize CS treatment strategies.
  • Advances in therapy offer improved outcomes for CS patients, particularly those with acute myocardial infarction.

Keywords:
cardiogenic shockinotropesmechanical circulatory support

More Related Videos

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.2K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.5K

Related Concept Videos

Blood Pressure Imbalances and Circulatory Shock01:24

Blood Pressure Imbalances and Circulatory Shock

Disorders affecting blood volume, vascular tone, or vascular function can disrupt vascular homeostasis, including conditions like hypertension, hemorrhage, and shock.
Blood Pressure: Hypertension and Hypotension
Normal blood pressure is 120/80 mm Hg. Elevated blood pressure is 120-129/under 80 mm Hg. Hypertension, warranting treatment at 130/80 mm Hg, is often asymptomatic and can lead to severe cardiovascular events, aneurysms, peripheral arterial disease, chronic renal disease, or cardiac...
743
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
511
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
378
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
314
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
724
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
512